Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
OTONOMY, INC. (OTIC) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/25/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update  OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022  Enrollment nearly complete in OTO-413 Phase 2a cohort in hearing loss with results moved forward to early in second quarter of 2022  Initiating clinical safety evaluation of higher dosing for OTO-413 to support full dose-ranging Phase 2 efficacy trial expected to start by the end of 2022  OTO-825 IND-enabling activities ongoing with IND filing expected first half of 2023 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, November 10, 2021"
08/04/2021 8-K Quarterly results
Docs: "Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update"
05/11/2021 8-K Quarterly results
11/04/2020 8-K Quarterly results
Docs: "Enrollment completed in Phase 3 clinical trial of OTIVIDEX ® in Ménière’s disease with results expected in the first quarter of 2021 • Positive results reported for Phase 1/2 clinical trial of OTO-313 in tinnitus patients • Enrollment completed in Phase 1/2 clinical trial of OTO-413 in hearing loss with results expected by end of year • Public offering completed for total gross proceeds of $69.1 million Conference call and webcast today at 4:30 p.m. ET"
08/04/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
02/27/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s disease • Broadest pipeline in neurotology field expanded to include gene therapy collaboration targeting most common cause of congenital hearing loss • Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. ET"
08/01/2019 8-K Quarterly results
Docs: "Clinical-stage programs on track with results expected from three trials in 2020 • Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. EDT"
05/06/2019 8-K Quarterly results
Docs: "OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020 • OTIPRIO Ò co-promotion agreement completed with Glenmark Therapeutics • OTIVIDEXä Phase 3 trial in Ménière’s disease on track for results in first half of 2020 • OTO-413 Phase 1/2 trial in hearing loss expected to start in third quarter of 2019; results expected in second half of 2020 • Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. EDT"
03/04/2019 8-K Quarterly results
Docs: "OTIVIDEXä Phase 3 trial in Ménière’s disease on track for results in first half 2020 • OTO-313 Phase 1/2 trial in tinnitus expected to start in second quarter of 2019 • OTO-413 Phase 1/2 trial in hearing loss expected to start in third quarter of 2019 • $15 million term loan completed to extend cash runway into 2021 Conference call and webcast today at 4:30 p.m. EST"
11/05/2018 8-K Quarterly results
Docs: "Otonomy Reports Third Quarter 2018 Financial Results and Provides Corporate Update Conference call and webcast today at 4:30 p.m. EST"
08/08/2018 8-K Quarterly results
Docs: "EX-99..1"
05/09/2018 8-K Quarterly results
Docs: "Otonomy Reports First Quarter 2018 Financial Results and Provides Corporate Update Conference call and webcast today at 4:30 p.m. EDT"
03/08/2018 8-K Quarterly results
Docs: "Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update"
11/08/2017 8-K Quarterly results
Docs: "Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update",
"Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX ™ in Patients with Ménière's Disease"
08/03/2017 8-K Quarterly results
Docs: "Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update"
05/04/2017 8-K Form 8-K - Current report
03/02/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
05/09/2016 8-K Quarterly results
Docs: "Otonomy Reports First Quarter 2016 Financial Results and Provides Corporate Update SAN DIEGO, May 9, 2016 — Otonomy, Inc. , a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today reported financial results for the quarter ended March 31, 2016 and provided an update on its corporate activities and product pipeline. First Quarter 2016 and Subsequent Highlights"
11/10/2015 8-K Quarterly results
Docs: "Otonomy Reports Third Quarter 2015 Financial Results and Provides Corporate Update SAN DIEGO, November 10, 2015 — Otonomy, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today reported financial results for the quarter ended September 30, 2015 and provided an update on its corporate activities and product pipeline. Third Quarter 2015 and Subsequent Highlights"
08/12/2015 8-K Quarterly results
Docs: "Otonomy Reports Second Quarter 2015 Financial Results and Provides Corporate Update SAN DIEGO, August 12, 2015 — Otonomy, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today reported financial results for the quarter ended June 30, 2015 and provided an update on its corporate activities and product pipeline. Second Quarter 2015 and Subsequent Highlights"
05/12/2015 8-K Quarterly results
Docs: "Otonomy Reports First Quarter 2015 Financial Results and Provides Corporate Update SAN DIEGO, May 12, 2015 — Otonomy, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today reported financial results for the quarter ended March 31, 2015 and provided an update on its corporate activities and product pipeline. First Quarter 2015 and Subsequent Highlights"
11/12/2014 8-K Quarterly results
Docs: "Otonomy Reports Third Quarter 2014 Financial Results and Provides Corporate Update SAN DIEGO, November 12, 2014 — Otonomy, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today reported financial results for the third quarter ended September 30, 2014. Third Quarter 2014 and Subsequent Highlights"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy